Immuron Limited CEO Steven Lydeamore joined Steve Darling from Proactive to share news about the Australian Biotech company that is looking at using its technology for product development around gut health. Lydeamore telling Proactive more about the products in its pipeline including Travelan which the company has recently completed a pre-IND meeting with the U.S. Food and Drug administration and has commenced work on an investigational new drug application.
Immuron working towards US FDA approval of Traveler’s Diarrhea product Travelan
